Composition and methods employing it for the treatment of 5-HT-mediated disorders
US6172105A · kind A · utility
4Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 1999 |
| Grant date | Jan 9, 2001 |
| Priority date | — |
| Expiry date | Jul 9, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxa mide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is a 5-HT reuptake inhibitor, excluding citalopram and paroxetine. The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.